CRL Stock: Charles River Laboratories International, Inc. Stock Price, Analysis & Insights
Get live crl stock price $167.70, comprehensive Charles River Laboratories International, Inc. stock analysis, charts, news, and expert forecast. Real-time crl stock data and investment insights.
Loading chart...
Company Overview
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Company Information
- CEO
- James C. Foster
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 18700
Contact Information
- Website
- https://www.criver.com
- Address
- 251 Ballardvale Street
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Higher growth potential with elevated volatility (Beta: 1.64)
Business Model & Strategy
Charles River Laboratories International, Inc. operates in the Medical - Diagnostics & Research industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO James C. Foster, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Medical - Diagnostics & Research model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Charles River Laboratories International, Inc. competes in the Medical - Diagnostics & Research within the broader Healthcare. With 8.3 billion in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the New York Stock Exchange, Charles River Laboratories International, Inc. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Charles River Laboratories International, Inc. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Charles River Laboratories International, Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Charles River Laboratories International, Inc.
- ⚠Investors should consider how Charles River Laboratories International, Inc. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
8.25B
P/E Ratio
-129.00
Beta
1.64
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 8.25B market capitalization
- Trading Volume: 2.61M shares traded today
- Price Range: 52-week range of $91.86 - $230.02
- Exchange: Listed on New York Stock Exchange
Financial Metrics
Market Analysis for Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. (CRL) operates in the Medical - Diagnostics & Research industry within the Healthcare sector. With a current market capitalization of 8.25B, the company represents a significant player in its market. The stock is currently trading at $167.70 with a negativedaily change of 5.71%.
The company's 18700 employee base and presence on the New York Stock Exchangeexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -129.00, beta of 1.64, and 52-week price range from $91.86 to $230.02when evaluating investment opportunities.
Why Invest in Charles River Laboratories International, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (New York Stock Exchange)
- • Experienced leadership under James C. Foster
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.